Zogenix (ZGNX) Announces Positive Phase 3 Trial Results on Efficacy and Safety of FINTEPLA in Dravet Syndrome
Tweet Send to a Friend
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, announced today that late-breaking ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
